MPX Bioceutical Corp

Equities

MPX

CA5534431021

Delayed Canadian Securities Exchange Other stock markets			5-day change	1st Jan Change
- ^CAD	-.--%		+5.36%	+34.09%

2020	IAnthus and MPX Bioceutical Receives Demand for Payment and Notice of Intention to Enforce Security	CI
2019	IAnthus Capital Holdings, Inc. completed the acquisition of MPX Bioceutical Corporation.	CI

MPX Bioceutical Corporation Reports Earnings Results for the Third Quarter Ended December 31, 2017; Provides Revenue Guidance for the Fourth Quarter of 2018

March 01, 2018 at 05:30 pm IST

MPX Bioceutical Corporation reported earnings results for the third quarter ended December 31, 2017. For the quarter, the company reported revenue of CAD 4.5 million. Adjusted LBITDA was CAD 1.2 million. Net loss was CAD 13 million. Net cash used in operations was CAD 3.4 million.

Revenue for the fourth quarter is expected to be CAD 6 million.

Latest news about MPX Bioceutical Corp

IAnthus and MPX Bioceutical Receives Demand for Payment and Notice of Intention to Enforce Security	23/20/23	CI
IAnthus Capital Holdings, Inc. completed the acquisition of MPX Bioceutical Corporation.	05/19/05	CI
MPX Bioceutical Corporation completed the spin off of MPX International Corporation for CAD 56.6 million.	05/19/05	CI
MPX Bioceutical Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended September 30, 2018	30/18/30	CI
MPX Bioceutical Corporation Expands Maryland Footprint with Opening of Health for Life White Marsh Dispensary	30/18/30	CI
iAnthus Capital Holdings, Inc. and MPX Bioceutical Corporation Signs Arrangement Agreement	18/18/18	CI
IAnthus Capital Holdings, Inc. entered into an agreement to acquire MPX Bioceutical Corporation for approximately CAD 520 million.	18/18/18	CI
MPX Bioceutical Corporation signed an arrangement agreement to spin off MPX International Corporation.	18/18/18	CI
MPX Bioceutical Corporation Opens its New Health for Life Dispensary in Baltimore, Maryland	12/18/12	CI
MPX Bioceutical Corporation completed the acquisition of Spartan Wellness Corporation from Ninth Square Capital Corporation and Veteran Grown Corporation.	30/18/30	CI
MPX Bioceutical Corporation entered into a binding share purchase agreement to acquire Spartan Wellness Corporation from Ninth Square Capital Corporation and Veteran Grown Corporation for CAD 2.9 million.	19/18/19	CI
MPX Bioceutical Corporation Provides Update on GreenMart of Nevada NLV LLC	18/18/18	CI
Canada's maturing Big Weed hits up Europe hoping for expansion cash	13/18/13	RE
MPX Bioceutical Corporation Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2018	30/18/30	CI
MPX Bioceutical Corporation Announces Opening of its First Health for Life Dispensary in Maryland	25/18/25	CI
MPX Bioceutical Corporation Announces Opening of its First Health for Life Dispensary in Maryland, Located in Downtown Bethesda	25/18/25	CI
MPX Bioceutical Corporation Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2018	03/18/03	CI
MPX Bioceutical Corporation Appoints David McLaren as Chief Financial Officer	02/18/02	CI
MPX Bioceutical Corporation completed the acquisition of ABACA, LLC.	02/18/02	CI
MPX Bioceutical Corporation Postpones Filing Date of 2018 Annual Statements	31/18/31	CI
MPX Bioceutical Corporation Enters Into Extraction Agreement With Case Farms Collective	19/18/19	CI
MPX Bioceutical Corporation Secures Final Approval to Open First Managed Dispensary in Maryland	17/18/17	CI
Robert Petch Joins the Board of Directors of MPX Bioceutical Corporation	07/18/07	CI
MPX Bioceutical Corporation completed the acquisition of 8423695 Canada Inc. for CAD 22.5 million.	07/18/07	CI
MPX Bioceutical Plans To Raise Funds	29/18/29	CI

Chart MPX Bioceutical Corp

Duration

Period

More charts

Company Profile

MPX Bioceutical Corp, formerly Canadian Bioceutical Corp, is Canada-based company which produces nutraceutical products intended for the treatment of chronic medical conditions where existing treatments fail to meet the needs of patients or where consumers prefer herbal and plant-based medicines out of their concern for the side effects associated with modern pharmaceutical medicines. Its products include CinG-X, Relieva and FertaMax. CinG-X combines standardized cinnamon and ginseng extracts. CinG-X is also an additive that enhances the value of any food, beverage or nutritional supplement and can be combined with various other ingredients. The Company's extract, Psorberine, has been incorporated into both topical cream and lotion products sold under the brand name Relieva. The Company intends to acquire companies engaged in the supply of management and logistical services to medical marijuana dispensaries, production and cultivation businesses in the United States.

Sector

More about the company